FTISADTSK-13C6,15N2 (TFA)

Product Description: FTISADTSK-13C6,15N2 TFA is 13C- and 15N-labeled FTISADTSK (HY-P3146). FTISADTSK is an endogenous stable signature peptide from Trastuzumab monitored by selected reaction monitoring (SRM)[1][2].

Applications: Cancer-programmed cell death

Formula: C38 13C6H69F3N8 15N2O18

References: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-220./[2]Bults P, et al. LC-MS/MS-Based Monitoring of In Vivo Protein Biotransformation: Quantitative Determination of Trastuzumab and Its Deamidation Products in Human Plasma. Anal Chem. 2016;88(3):1871-1877.

Molecular Weight: 1091.01

Compound Purity: 99.02

Research Area: Cancer

Solubility: DMSO : 100 mg/mL (ultrasonic)

Target: Isotope-Labeled Compounds

• Artikelnummer: MEXHY-P3146S-5
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P3146S-5
• Green Labware: Nein
• Verpackungseinheit: 5 mg
• Mengeneinheit: STK